Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Allakos Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 8,203,332 shares of common stock of…
Davis Polk Advises Auris Medical Holding AG on Its Offering of Common Shares and Warrants
Davis Polk advised Auris Medical Holding AG on a public offering of common shares and warrants. The common shares are listed…
CytomX Therapeutics, Inc. Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of…
Natera, Inc. $103.5 Million Follow-On Public Offering
Davis Polk advised the representatives of the underwriters in connection with the follow-on offering of 5,175,000…
Davis Polk Advises Entera Bio Ltd. on Its Initial Public Offering
Davis Polk advised Entera Bio Ltd. on its initial public offering of 1,400,000 ordinary shares and 1,400,000 warrants to…
Forty Seven, Inc. $112.6 Million Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 7,035…
Magenta Therapeutics, Inc. Initial Public Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $100…
Aptinyx Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 7,359,998 shares of common stock of…
Davis Polk Advises Roche on Its Acquisition of Foundation Medicine
Davis Polk is advising Roche on its acquisition of the outstanding shares of Foundation Medicine, Inc. not already owned by…
Davis Polk Advises Kadmon Holdings, Inc. on Its Follow-on Offering of Common Stock
Davis Polk advised Kadmon Holdings, Inc. in connection with a $113.2 million offering of 32,022,728 shares of common stock,…